FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Drug Recall-Ready Tips

A CDER podcast gives drug companies steps to follow to be better able to handle recalls quickly and efficiently.

2019 NARMS Integrated Summary Out

FDA releases the 2019 National Antimicrobial Resistance Monitoring System Integrated Summary showing that salmonella resistance in humans remained ste...

Human Drugs

American Regent Production Supervisor Sentenced

The Justice Department says an American Regent drug production supervisor has been sentenced to jail time and payment of restitution for stealing thou...

Human Drugs

Study on Physician Use of Off-label Unsupportive Data

A new study about the influence of data disclosures on physician decisions about off-label uses suggests that there is limited awareness of, and expos...

FDA General

FDA Needs Procedures for Reporting Political Interference: GAO

A new Government Accountability Office report recommends that FDA and other HHS agencies develop procedures for reporting and addressing allegations o...

Human Drugs

FDA Rejects Teva/MedinCell Risperidone NDA

FDA issues Teva Pharmaceuticals and MedinCell a complete response letter on their NDA for TV-46000/mdc-IRM (risperidone extended-release injectable su...

Federal Register

NCTR Science Advisory Board Panel Meeting

Federal Register notice: FDA announces a 5/18-19 meeting of the Science Advisory Board to the National Center for Toxicological Research (NCTR) Adviso...

Human Drugs

Center for Rare Neurological Diseases Warned on 2 Trials

FDA warns the Norcross, GA-based Center for Rare Neurological Diseases about human subject protection violations in its conduct of two clinical trials...

Federal Register

Published Literature Used for Animal Drugs Guide

Federal Register notice: FDA makes available a draft guidance for industry #106 entitled The Use of Published Literature in Support of New Animal Drug...

Federal Register

FDA Corrects ANDA Withdrawal Notice

Federal Register notice: FDA corrects a 2/28 notice announcing the withdrawal of approval of five ANDAs from multiple applicants.